Good news here… Do trial benefits predict real-world gains in metastatic castration resistant prostate cancer?

[Broccoli24]

This study examined the relationship between drug efficacy in randomized clinical trials (RCTs) and real-world effectiveness for metastatic castration-resistant #ProstateCancer (mCRPC) drugs. By analyzing pharmaceutical therapies approved between 2010 and 2019, the researchers compared overall survival (OS) and radiographic progression-free survival (rPFS) hazard ratios from RCTs to real-world OS outcomes. Initially, real-world OS gains appeared 15% lower than RCT predictions due to treatment selection bias, but after accounting for this bias, real-world OS gains were 28% greater than RCT estimates.

So… RCT results may give us conservative estimates of actual OS & rPFS… which maybe feels like pretty positive news.

Source - academic.oup.com/jncics/adv...